CELL INTELLIGENCE · 肿瘤细胞治疗研究

序贯自体干细胞移植与 Ciltacabtagene Autoleucel 治疗一例系统性红斑狼疮患者并发的多发性骨髓瘤及疑似免疫球蛋白重链和轻链淀粉样变性

Sequential Autologous Stem Cell Transplantation and Ciltacabtagene Autoleucel for Concurrent Multiple Myeloma and Presumptive Immunoglobulin Heavy- an

尽管有新疗法，多发性骨髓瘤的死亡率改善仍在放缓：1990-2023 年按社会人口指数划分的全球差异

Slowing Mortality Improvements in Multiple Myeloma Despite Novel Therapies: Global Disparities by Sociodemographic Index, 1990-2023.

CRISPR/Cas9 在癌症治疗中的应用：临床转化、机制策略与治疗方向

CRISPR/Cas9 in cancer therapy: clinical translation, mechanistic strategies, and therapeutic directions.

智胜抗原逃逸：用于血液系统恶性肿瘤持久缓解的下一代 CAR-T 细胞工程策略

Outsmarting Antigen Escape: Next-Generation CAR T Cell Engineering Strategies for Durable Remissions in Hematologic Malignancies.

Idecabtagene Vicleucel 后 100 天内的感染及其对复发/难治性多发性骨髓瘤生存的影响：一项 CIBMTR 分析

Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis.

多发性骨髓瘤中的单特异性和双特异性嵌合抗原受体（CAR）T 细胞治疗：系统综述、荟萃分析与荟萃回归

Monospecific and Bispecific Chimeric Antigen Receptor (CAR) T-cell Therapy in Multiple Myeloma: A Systematic Review, Meta-analysis and Meta-regression

全人源 BCMA CAR-T 治疗多发性骨髓瘤：长期随访的启示

Fully human BCMA CAR-T therapy in multiple myeloma: lessons from long-term follow-up.

下一代肿瘤免疫治疗：CAR-T 细胞治疗的前景

Next-generation cancer immunotherapy: the promise of CAR T-Cell therapy.

靶向肿瘤坏死因子受体超家族成员 8 (CD30) 的 CAR-T 细胞治疗用于复发/难治性间变性大细胞淋巴瘤：原理、策略和新兴临床证据

Chimeric Antigen Receptor T‑Cell Therapy Targeting Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30) for Relapsed or Refractory Anaplastic La

结合 CRISPR/Cas9 介导的 TRAC 敲除与基于 mRNA 的 CAR 表达实现异体 CAR-T 细胞的灵活制备

Combining CRISPR/Cas9-mediated TRAC knockout with mRNA-based CAR expression enables flexible generation of allogeneic CAR T cells.

这些发现建立了一个利用 mRNA 技术生产同种异体 CAR-T 细胞的模块化平台，为快速、按需的 CAR-T 细胞疗法提供了一种实用方法。